Label: VARDENAFIL tablet, orally disintegrating
rufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
8.5 Geriatric Use
primaquineprimaquine and vardenafil both increase QTc interval. primaquine and vardenafil both increase QTc interval. primidoneprimidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by QTc interval.
Experts Discuss the Potential Role of GLP-1 Receptor Agonists in Breast Cancer Outcomes and Survivorship Care
Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. quininevardenafil and quinine both increase QTc interval. vardenafil cenforce 200 tablets and quinine both increase QTc interval. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
Erectile Dysfunction
relacorilantrelacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with a strong CYP3A4 inhibitor. relacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec revumenib and vardenafil both increase QTc interval. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec ribociclibribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selpercatinibselpercatinib increases toxicity of vardenafil by QTc interval.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Original | 20mg | 8 Pills | 61.70€ 58.76€ | |
| Levitra Generic | 60mg | 360 + 10 Pills | 906.69€ 863.51€ | |
| Priligy Generic Dapoxetine | 60mg | 10 Pills | 47.63€ 45.36€ | |
| Cialis Soft Tabs | 20mg | 30 + 4 Pills | 87.43€ 83.27€ | |
| Levitra Original | 20mg | 120 + 8 Pills | 528.19€ 503.04€ | |
| Kamagra Polo | 100 mg | 60 + 4 Pills | 189.39€ 180.37€ | |
| Cialis Black | 80mg | 120 + 8 Pills | 264.77€ 252.16€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Kamagra Oral Jelly | 100mg | 10 Sachets | 54.55€ 51.95€ | |
| Kamagra Polo | 100 mg | 84 + 4 Pills | 244.49€ 232.85€ | |
| Kamagra 100 mg | 100 mg | 12 Pills | 55.64€ 52.99€ | |
| Viagra Generic | 150mg | 180 + 10 Pills | 236.46€ 225.20€ | |
| Kamagra Gold | 100 mg | 360 + 6 Pills | 839.95€ 799.95€ |
selpercatinib increases toxicity of vardenafil by QTc interval. Coadministration of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure. sertralinesertraline and vardenafil both increase QTc interval. sertraline and vardenafil both increase QTc interval.
Do erectile dysfunction medicines increase sexual desire?
rilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
| Patient Type | Recommended Dose | Notes |
|---|---|---|
| Adult Men with ED | 10 mg | 1 hour before activity |
| Elderly Patients | 5-10 mg | Adjust based on tolerability |
| Patients with Liver Impairment | 5 mg | Lower dose recommended |
| Use with CYP3A4 inhibitors | 5 mg | To reduce adverse risk |
sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of vardenafil by QTc interval.
- The onset of vardenafil 10 mg is typically 30-60 minutes.
- It can last up to 4-5 hours in some users.
- Vardenafil is contraindicated with certain heart medications.
- Use caution if you have a history of hypotension.
- The tablet may cause mild gastrointestinal upset.
- Do not consume large amounts of alcohol when taking vardenafil.
- Inform your doctor if you experience sudden hearing loss.
- Use only as directed by your healthcare provider.
- Discontinue if you experience persistent erection issues.
- The medication does not increase sexual desire.
sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of vardenafil by QTc interval. solifenacinsolifenacin and vardenafil both increase QTc interval.
- Some users may experience mild flickering vision episodes.
- The efficacy of vardenafil varies between individuals.
- The medication is available in various dosage forms.
- Always follow the specific instructions provided.
- Avoid taking vardenafil with high-fat meals to speed absorption.
- Do not take vardenafil if allergic to its ingredients.
- The drug may cause a temporary burning sensation.
- Use caution in patients with a history of priapism.
- Avoid combining vardenafil with certain herbal supplements.
- Consult your doctor about any ongoing health treatments.
solifenacin and vardenafil both increase QTc interval.
5.10 Combination with Other Erectile Dysfunction Therapies
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors rifapentinerifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with moderate CYP3A inhibitors. sorafenibsorafenib and vardenafil both increase QTc interval. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. sunitinibsunitinib and vardenafil both increase QTc interval.
Membership Benefits
osimertinib and vardenafil both increase QTc interval. ozanimodozanimod and vardenafil both increase QTc interval. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. ozanimod and vardenafil both increase QTc interval. vardenafil and pasireotide both increase QTc interval.
What are the most common side effects of vardenafil?
pentobarbitalpentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Vardenafil Side Effects
phenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazoleposaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors posaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors prednisoneprednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sunitinib and vardenafil both increase QTc interval. suzetriginesuzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic indexes when coadministered with suzetrigine. Consider modifying dose of sensitive substrate according to prescribing recommendations. suzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use may increase the risk of QTc interval prolongation. If concomitant use is unavoidable, adjust the frequency of ECG and electrolyte monitoring.
Side Effects
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetronnetupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nevirapinenevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Professional resources
nifedipinenifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinibnilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/72 hr olanzapineolanzapine and vardenafil both increase QTc interval.
Pulmonary Arterial Hypertension (Orphan)
olanzapine and vardenafil both increase QTc interval. olodaterol inhaledvardenafil and olodaterol inhaled both increase QTc interval. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias vardenafil and olodaterol inhaled both increase QTc interval. osilodrostat and vardenafil both increase QTc interval. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval. tecovirimattecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Vardenafil is ineffective without sexual arousal.
- It does not protect against sexually transmitted infections.
- Avoid excessive mental or physical exertion while on medication.
- Consult a healthcare professional if unsure about interactions.
- Don't take vardenafil if you've had recent heart attack.
- Use with caution if you have a bleeding disorder.
- Medication may cause a temporary drop in blood pressure.
- Avoid using if you have a known hypersensitivity.
- The pill should be taken as part of a treatment plan.
- Keep track of how you respond to the medication.
Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
| Region | Average Price (per tablet) | Availability | Notes |
|---|---|---|---|
| North America | $2 - $5 | Widely available | Prescription required |
| Europe | €2 - €4 | Available at pharmacies | Generic options common |
| Asia | $1 - $3 | Readily available | Often lower cost |
| Africa | $2 - $4 | Varies by country | May require import or special order |
tecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tetracyclinetetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
- Vardenafil 10 mg is a popular choice for ED treatment.
- Dose can be adjusted by a healthcare provider.
- Avoid using vardenafil with recreational drugs like poppers.
- Do not use after consuming large amounts of alcohol.
- The pill is generally taken before planned intercourse.
- Its effects are dose-dependent and subject to individual variation.
- Adherence to prescribed dose helps prevent adverse effects.
- The medication can be used long-term if prescribed.
- Regular checkups can help monitor effectiveness and safety.
- Never double the dose if the first does not work immediately.
Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tobramycin inhaledtobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity tobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity topiramatetopiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Site Operator
Fabienne Heyne
[email protected]
Corporate Design
Silvio Ketterer Visuelle Gestaltung
www.silvioketterer.ch
Website Programming
RHOdesign
www.rhodesign.ch
Photography
Angelika Annen
www.angelikaannen.ch